Valuation & Prioritization Techniques to Optimize Your R&D Portfolio

Developing new drug products is an extremely long and expensive process and only a small percentage of compounds in research perform well enough to progress through development and gain approval. Furthermore, the biopharmaceutical landscape is evolving under increasing budget pressures, heightened competition and patent expiration. Amidst these environmental changes, regulatory scrutiny and budgetary challenges, today’s pharmaceutical and biotech companies are facing more pressure than ever to make effective and strategic decisions regarding their R&D pipeline. Learn from industry thought leaders and benchmark with peers as you navigate this challenging terrain to enhance your R&D pipeline through strategic target selection, valuation and prioritization of R&D

Targeted topics and highlights include:

• Identifying and targeting promising indications to drive R&D strategy
• Aligning portfolio with corporate strategy and goal-setting
• Valuation strategies and metrics for assessing commercial opportunities of developmental compounds
• Financial analysis of targets in global licensing and acquisition activities
• Project, program and document management practices
• Transitioning from R&D portfolio planning to branded lifecycle management
• Strategic asset planning and allocation for short, medium and long-term resources

Get a Brochure for more information or Register Now Online